1. A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY. (4th March 2021) Authors: Feagan, B G; Loftus, E V; Danese, S; Vermeire, S; Sandborn, W J; Ritter, T; Mehta, R; Seidler, U; Seibold, F; Beales, I; Kim, H; McNally, J; Yun, C; Zhao, S; Liu, X; Tasset, C; Besuyen, R; Watanabe, M; Schreiber, S; Rogler, G Journal: Journal of the Canadian Association of Gastroenterology Issue: Volume 4(2021)Supplement 1 Page Start: 18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OC-007 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), AHuman MAB to IL-12/23P40, IN PTS with Moderately-Severely Active Crohn's Disease (CD) Who are Naïve or not Refractory to anti-TNFΑ: UNITI-2. (17th August 2016) Authors: Feagan, B; Gasink, C; Lang, Y; Friedman, JR; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Rutgeerts, P; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Tulassay, Z; Seidler, U; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases. (30th January 2023) Authors: Pueschel, L; Kockelmann, F; Kueck, M; Tegtbur, U; Seidler, U; Lenzen, H; Attaran-Bandarabadi, M; Bachmann, O; Wedemeyer, H; Wiestler, M Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i671 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗